Succinic Acid

Succinic Acid

SCHEMBL28760118

NCCCCC(C(=O)O)C(=O)OCC1c2ccccc2-c2ccccc21.O=C(O)CCC(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
TLR2 O60603 4/20 0.42
FABP5 Q01469 3/20 0.42
FABP7 O15540 2/20 0.42
CASP3 P42574 2/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
EPHX2 P34913 1/20 0.38
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
MDM4 O15151 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25144 0.95 KMT2A (0.49) KMT2ATLR2FABP5FABP7CASP3
SCHEMBL3426738 0.94 KMT2A (0.48) KMT2ATLR2FABP5FABP7CASP3
SCHEMBL3976225 0.94 KMT2A (0.48) KMT2ATLR2FABP5FABP7CASP3
SCHEMBL524835 0.94 KMT2A (0.48) KMT2ATLR2FABP5FABP7CASP3
SCHEMBL524545 0.94 KMT2A (0.48) KMT2ATLR2FABP5FABP7CASP3
SCHEMBL28036073 0.94 KMT2A (0.48) KMT2ATLR2FABP5FABP7CASP3
SCHEMBL525558 0.94 KMT2A (0.48) KMT2ATLR2FABP5FABP7CASP3
SCHEMBL97613 0.91 KMT2A (0.50) KMT2ATLR2FABP5FABP7CASP3
Tetrahydrofuran SCHEMBL28301142 0.88 KMT2A (0.43) KMT2ATLR2FABP5FABP7CASP3
SCHEMBL28463133 0.86 KMT2A (0.48) KMT2ATLR2FABP5FABP7CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230116771-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE REGENERON PHARMACEUTICALS, INC. 2023-04-13 US disclosed
EP-3408271-B1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE REGENERON PHARMA (US) 2023-01-11 EP disclosed
US-11446389-B2 Maytansinoid derivatives, conjugates thereof, and methods of use REGENERON PHARMACEUTICALS, INC. (US) 2022-09-20 US disclosed
CN-108779127-B Maytansinoid derivatives, conjugates thereof, and methods of use 里珍纳龙药品有限公司 2022-07-05 CN disclosed
CN-114478801-A Maytansinoid derivatives, conjugates thereof, and methods of use 里珍纳龙药品有限公司 2022-05-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230116771-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE HNMT, SLC10A1, SLC10A2 KMT2A 3743/4885TLR2 2898/4885FABP5 3239/4885
US-11446389-B2 Maytansinoid derivatives, conjugates thereof, and methods of use HNMT, SLC10A1, SLC10A2 KMT2A 3743/4885TLR2 2898/4885FABP5 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.